Connection

Francis Spinale to Myocardium

This is a "connection" page, showing publications Francis Spinale has written about Myocardium.
Connection Strength

8.566
  1. The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. Am J Physiol Heart Circ Physiol. 2020 10 01; 319(4):H765-H774.
    View in: PubMed
    Score: 0.462
  2. In vivo assessment of regional mechanics post-myocardial infarction: A focus on the road ahead. J Appl Physiol (1985). 2017 Oct 01; 123(4):728-745.
    View in: PubMed
    Score: 0.362
  3. Assessment of Cardiac Function--Basic Principles and Approaches. Compr Physiol. 2015 Sep 20; 5(4):1911-46.
    View in: PubMed
    Score: 0.328
  4. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 01; 7(2):340-50.
    View in: PubMed
    Score: 0.292
  5. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
    View in: PubMed
    Score: 0.272
  6. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol. 2013 Mar 01; 304(5):C393-402.
    View in: PubMed
    Score: 0.270
  7. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
    View in: PubMed
    Score: 0.268
  8. Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012 Jan; 8(1):7-20.
    View in: PubMed
    Score: 0.254
  9. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.246
  10. Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar; 13(3):271-7.
    View in: PubMed
    Score: 0.236
  11. Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. Am J Physiol Heart Circ Physiol. 2010 Dec; 299(6):H1947-58.
    View in: PubMed
    Score: 0.233
  12. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
    View in: PubMed
    Score: 0.229
  13. Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J Nucl Med. 2010 May 01; 51 Suppl 1:102S-106S.
    View in: PubMed
    Score: 0.225
  14. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
    View in: PubMed
    Score: 0.211
  15. Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation. 2008 Sep 30; 118(14 Suppl):S16-23.
    View in: PubMed
    Score: 0.202
  16. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
    View in: PubMed
    Score: 0.200
  17. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 Oct; 87(4):1285-342.
    View in: PubMed
    Score: 0.189
  18. Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol. 2007 Oct; 293(4):C1362-73.
    View in: PubMed
    Score: 0.187
  19. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.
    View in: PubMed
    Score: 0.172
  20. Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol. 2006 Apr; 40(4):474-83.
    View in: PubMed
    Score: 0.169
  21. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006 Feb 15; 69(3):666-76.
    View in: PubMed
    Score: 0.168
  22. Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation. 2005 Aug 30; 112(9):1274-83.
    View in: PubMed
    Score: 0.163
  23. Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
    View in: PubMed
    Score: 0.160
  24. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res. 2005 May 27; 96(10):1110-8.
    View in: PubMed
    Score: 0.160
  25. Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Mar; 129(3):584-90.
    View in: PubMed
    Score: 0.158
  26. Disruptions and detours in the myocardial matrix highway and heart failure. Curr Heart Fail Rep. 2005 Mar; 2(1):10-7.
    View in: PubMed
    Score: 0.158
  27. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
    View in: PubMed
    Score: 0.156
  28. Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res. 2004 Sep 03; 95(5):446-8.
    View in: PubMed
    Score: 0.153
  29. Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1892-9.
    View in: PubMed
    Score: 0.145
  30. Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol. 2003 May; 35(5):539-48.
    View in: PubMed
    Score: 0.139
  31. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.137
  32. Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circ Res. 2002 Dec 13; 91(12):1082-4.
    View in: PubMed
    Score: 0.135
  33. Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction. Heart Rhythm. 2022 05; 19(5):847-855.
    View in: PubMed
    Score: 0.127
  34. Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling. Circ Cardiovasc Imaging. 2019 11; 12(11):e009055.
    View in: PubMed
    Score: 0.109
  35. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):636-46.
    View in: PubMed
    Score: 0.085
  36. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014 May; 70:92-9.
    View in: PubMed
    Score: 0.073
  37. Integrating the myocardial matrix into heart failure recognition and management. Circ Res. 2013 Aug 30; 113(6):725-38.
    View in: PubMed
    Score: 0.071
  38. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
    View in: PubMed
    Score: 0.069
  39. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.064
  40. Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy. J Cardiovasc Pharmacol. 2011 Apr; 57(4):400-6.
    View in: PubMed
    Score: 0.060
  41. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. J Surg Res. 2012 Jan; 172(1):59-67.
    View in: PubMed
    Score: 0.057
  42. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol. 2010 Jul; 134(1):23-30.
    View in: PubMed
    Score: 0.057
  43. Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms. J Cardiovasc Pharmacol. 2010 Apr; 55(4):408-16.
    View in: PubMed
    Score: 0.056
  44. Temporally and regionally disparate differences in plasmin activity by tranexamic acid. Anesth Analg. 2010 Mar 01; 110(3):694-701.
    View in: PubMed
    Score: 0.056
  45. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.054
  46. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail. 2009 May; 2(3):262-71.
    View in: PubMed
    Score: 0.053
  47. Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct; 52(4):355-62.
    View in: PubMed
    Score: 0.051
  48. Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg. 2008 Aug; 86(2):568-75.
    View in: PubMed
    Score: 0.050
  49. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006 Jun 27; 113(25):2919-28.
    View in: PubMed
    Score: 0.043
  50. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol. 2006 Feb; 47(2):228-35.
    View in: PubMed
    Score: 0.042
  51. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.042
  52. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.039
  53. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation. 2005 Mar 08; 111(9):1166-74.
    View in: PubMed
    Score: 0.039
  54. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004 Oct; 37(4):801-11.
    View in: PubMed
    Score: 0.038
  55. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003 Oct 07; 108(14):1753-9.
    View in: PubMed
    Score: 0.036
  56. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003 Aug 05; 108(5):598-604.
    View in: PubMed
    Score: 0.035
  57. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
    View in: PubMed
    Score: 0.034
  58. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol. 2003 Jan; 284(1):H122-32.
    View in: PubMed
    Score: 0.034
  59. Extracellular matrix remodeling following myocardial injury. Ann Med. 2003; 35(5):316-26.
    View in: PubMed
    Score: 0.034
  60. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
    View in: PubMed
    Score: 0.034
  61. The extracellular matrix: summation. J Card Fail. 2002 Dec; 8(6 Suppl):S349-50.
    View in: PubMed
    Score: 0.034
  62. Matrix Metalloproteinase-Targeted SPECT/CT Imaging for Evaluation of Therapeutic Hydrogels for the Early Modulation of Post-Infarct Myocardial Remodeling. J Cardiovasc Transl Res. 2023 Feb; 16(1):155-165.
    View in: PubMed
    Score: 0.033
  63. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1288-95.
    View in: PubMed
    Score: 0.032
  64. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
    View in: PubMed
    Score: 0.032
  65. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
    View in: PubMed
    Score: 0.014
  66. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.012
  67. Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev. 2005 Jun; 10(2):125-39.
    View in: PubMed
    Score: 0.010
  68. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004 Jan 20; 109(2):262-8.
    View in: PubMed
    Score: 0.009
  69. Myocardial remodeling after discrete radiofrequency injury: effects of tissue inhibitor of matrix metalloproteinase-1 gene deletion. Am J Physiol Heart Circ Physiol. 2004 Apr; 286(4):H1242-7.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.